Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Seen As The Prize In The Race For HCV Dominance

This article was originally published in PharmAsia News

Executive Summary

As Gilead and AbbVie battle for new hepatitis C treatment options, Roche is hoping a trailing product can find a home in China, where genotype 1b HCV is most prevalent.

You may also be interested in...



Gilead Phase III Program For Two-Drug HCV Combo On Faster Pace Than Expected

Company also updates Phase II ELECTRON data from November, showing all nine patients in a null-responder cohort achieved sustained virological response after four weeks of therapy with combo.

Incivek Black Box Creates Fallout Risk For Vertex, FDA On Rash-related Fatalities

For Vertex, the key question is how much is physician and patient concern about the adverse events is already reflected in the softening sales of the hepatitis C drug; for FDA, the question is how effective will label-based risk management be.

China’s Simcere Receives Buyout Offer From Its Chairman, But Could Delisting Be A Negative Overseas?

Simcere would join Chinese firms 3SBio and ShangPharma in pulling out of the U.S. stock market.

Topics

Related Companies

UsernamePublicRestriction

Register

RS009715

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel